Pieris Pharmaceuticals Inc
NASDAQ:PIRS

Watchlist Manager
Pieris Pharmaceuticals Inc Logo
Pieris Pharmaceuticals Inc
NASDAQ:PIRS
Watchlist
Price: 12.0296 USD -27.16% Market Closed
Market Cap: $100.1m

Operating Margin

-1 338.5%
Current
Declining
by 1 072.5%
vs 3-y average of -266%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-1 338.5%
=
Operating Income
$-18.1m
/
Revenue
$1.4m

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-1 338.5%
=
Operating Income
$-18.1m
/
Revenue
$1.4m

Peer Comparison

Country Company Market Cap Operating
Margin
US
Pieris Pharmaceuticals Inc
NASDAQ:PIRS
100.1m USD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
387.5B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
185.5B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
168.8B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
119B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.3B USD
Loading...
AU
CSL Ltd
ASX:CSL
87B AUD
Loading...
NL
argenx SE
XBRU:ARGX
43.2B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
47.2B USD
Loading...

Market Distribution

Lower than 95% of companies in the United States of America
Percentile
5th
Based on 14 112 companies
5th percentile
-1 338.5%
Low
-4 087 900% — -5.1%
Typical Range
-5.1% — 14.8%
High
14.8% — 1 032 600%
Distribution Statistics
the United States of America
Min -4 087 900%
30th Percentile -5.1%
Median 6%
70th Percentile 14.8%
Max 1 032 600%

Pieris Pharmaceuticals Inc
Glance View

Market Cap
100.1m USD
Industry
Biotechnology

Pieris Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of Anticalin-based drugs. The company is headquartered in Boston, Massachusetts and currently employs 124 full-time employees. The company went IPO on 2014-12-18. The Company’s clinical pipeline includes an inhaled IL-4Rα antagonist Anticalin protein to treat asthma, an immuno-oncology (IO), bispecific targeting HER2 and 4-1BB, and an IO bispecific targeting PD-L1 and 4-1BB. Its lead respiratory Anticalin-based drug candidate, PRS-060/AZD1402, which is antagonizes IL-4R alpha, thereby inhibiting by IL-4 and IL-13, two cytokines, which are small proteins mediating signaling between cells within the human body, known to be mediators in the inflammatory cascade that drive the pathogenesis of asthma and other inflammatory diseases. The lead IO Anticalin-based drug candidate in its pipeline, cinrebafusp alfa, which is designed to target the immune receptor 4-1BB and the tumor target HER2. Cinrebafusp alfa is a genetic fusion of a variant of an HER2-targeting antibody with an Anticalin protein.

PIRS Intrinsic Value
1.4853 USD
Overvaluation 88%
Intrinsic Value
Price
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
-1 338.5%
=
Operating Income
$-18.1m
/
Revenue
$1.4m
What is Pieris Pharmaceuticals Inc's current Operating Margin?

The current Operating Margin for Pieris Pharmaceuticals Inc is -1 338.5%, which is below its 3-year median of -266%.

How has Operating Margin changed over time?

Over the last 3 years, Pieris Pharmaceuticals Inc’s Operating Margin has decreased from -214.2% to -1 338.5%. During this period, it reached a low of -1 338.5% on Sep 30, 2024 and a high of -37% on Dec 31, 2023.

Back to Top